SharpePoint’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.58M Buy
7,987
+121
+2% +$124K 4.8% 1
2026
Q1
$7.24M Buy
7,866
+82
+1% +$83.1K 4.31% 2
2025
Q4
$8.36M Buy
+7,784
New +$7.44M 5.01% 1
2025
Q2
Sell
-7,209
Closed -$6.38M 59
2025
Q1
$6.38M Sell
7,209
-2,220
-24% -$1.85M 5.59% 1
2024
Q4
$7.28M Buy
+9,429
New +$7.81M 6.56% 2

Other funds holding LLY

SharpePoint's LLY Position: Q2 2026 in Review

SharpePoint increased its Eli Lilly (LLY) stake by 1.5% in Q2 2026, buying an estimated $124K and bringing the position to 7,987 shares worth $9.58M. The position accounts for 4.8% of the portfolio, ranked #1.

SharpePoint first reported a position in LLY in Q4 2024 and has held it in 5 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • SharpePoint held 7,987 shares of Eli Lilly worth $9.58M as of Q2 2026.
  • SharpePoint bought 121 Eli Lilly shares in Q2 2026, an estimated $124K.
  • Eli Lilly made up 4.8% of SharpePoint's portfolio in Q2 2026, its #1 holding.
  • SharpePoint first reported a position in Eli Lilly in Q4 2024 and has held it in 5 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on SharpePoint's 13F filing for Q2 2026, filed 29 Jul 2026.